Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Well, I'm in for the long haul. Buying on the dips. She's gonna fly soon! And I'm ready.
Ahh good to know! Thanks! I just picked up 393,900 of the 400,000 at .0042. ;)
Thanks Atlanta. I guess I'll take that off. I just hate paying the $9.99 for each time haha.
Surf, I'm trying to load up on 825,000 shares at the ask price. It's not going thru. I have it ALL OR NOTHING. I tried splitting into two orders but still no good. Should I try without the all or nothing?
It won't take my order of 825,000 so I'm trying 300,000. It may be the All Or Nothing keeping it from going thru. :(
850,000 trying to go thru at .0041. Wish me luck!
Aern is not a scam. Hell all of my stocks were down today except dish and the market was up nicely. I'm not sure what's going on here today but when we get past it aern is going back up where it belongs. IMO
Thq's revenue so far from UFC is 45 million!!
Yes today was a boring, somewhat depressing day on most all of my stocks. I was off and hoping to see green everywhere but only red. I thought sure with good news we would have a good day! Well, there's always tomorrow! Eh Surf?
I'm expecting a huge announcement! They are setting the stage for it. Likely approval in Europe for iluvien, they've contracted out a company to manufacture their insert system for their drug, its the perfect time to make a huge announcement! Tomorrow will be huge! IMO I've loaded more today.
HOD $4.65! They are headed back up to the $8 range and I am shocked at the low volume and interest on here but hey, it's fine with me to not have all of those shorters messing things up for us! haha
GOOD MORNING SURF! Looking for a green week.
Alim has been holding its spot around $3.70-$3.80 nicely. With this news and future news the next few weeks alim should be back up to $8 and more. IMO
Alim is getting ready to rock and roll.
Surf, my friend, I'm backing up the truck again tomorrow and loading up a little extra on top of what I have now. Looking forward to an exciting week! Have a great Sunday!
I completely agree! They have several things going for them now that they have just started to get back on track. UFC 3 is selling thousands of copies, WWE, Saints Row are all doing good. They have trimmed out the areas of their business that's not making money so they can concentrate on the profitting areas. Even the CEO is taking a cut in his pay by half. Now all of these together makes me think this quarter we will see a very nice turn-around and THQ will be back over $1. IMO
Next Wednesday will be great because I'm off that day and can watch the money roll in! Hope you all have a great weekend!
Whats wrong with it is the fact all of the shorters come and go like lightening an don't allow aern to stay up!
I'm glad I've been with aern longer than a couple of weeks like some of you who seem to know it all haha.
Luckily, I believe Surf, and I'm like him in thinking I wish there would be a huge sell off so I, too, could load up another million or so shares! Haha GLTUA!
I'm thinking along the same lines.
I'll be one happy camper as well Atlanta! haha Patience is the key here. It's been said several times already. You just have to have patience. They can't release news every day! As soon as those guys get done drilling the new wells and reworking the old ones we are going to see black and green. In that order. ;)
I'm right there with you but I was there a couple of weeks ago when I was down $1,000 and within 2 days I was up $3,000 profit!! That was a great day and I sold and rebought twice with a .0069 average and I'm ready for the next surge because it's coming. Sure, AERN may drop more. Possibly down to .0030 again but I don't think so. Even if it does, when the oil revenue starts flowing in more this baby will take off again and those of us who stayed for the long haul will be sitting nicely! ;)
BTW I agree with what you said about the naysayers. And btw I wasn't referring to you when I said what I Did about moving on. I was talking to those naysayers. GLTA
Oh I'm not selling. I'd throw away my losses. I'm hoping that with the UFC, Saints Row, WWE and other games along with cutting back on the areas that are not profiting that this quarter will show a better company. That's what I stated in my last message. Good luck to us all!
MORE GREAT NEWS!! I was at work the other day and an employee of mine saw me looking at the Pulse Bev website and said 'I've had one of those! I got it in Mobile, AL. It was good!'. That makes an investor feel good. ;)
The Pulse Beverage Corporation (OTCBB: PLSB) ("Pulse"), makers of Cabanaâ„¢ 100% Natural Lemonade and Pulse® NutriPurposeâ„¢ brand beverages, today announced that it has secured distribution in Minnesota, through Norri Distributing based in northern Minnesota and established in 1951. Norri distributes a few major brands of beer including Miller and non-alcoholic beverages to the northern region of Minnesota. This agreement fills in a missing area in Minnesota that Bernicks Distributing does not reach. Norri recently bought out a local competitor who has increased Norri's breadth of brands and reach and they are committed to aggressively grow both the beer and non-alcoholic ends of their business. Bob Norri, CEO of Norri Distributing, said, "We look forward to selling and growing Cabana with its eye catching packaging and awesome taste."
Bob Yates, CEO of Pulse, said, "We are looking forward to working with Norri Distributing. They are a high quality distributor with a great reputation and have an aggressive approach to the market which will yield our partnership great rewards."
Details of the Company's business and agreements can be found as part of the Company's continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission's ("SEC") EDGAR database. For more information, please visit: www.pulsebeverage.com.
About The Pulse Beverage Corporation (OTCBB: PLSB)
If you think aern is such a disaster waiting to happen then why not move on and let us handle this?
I am starting to think the same way. It's absolutely ridiculous this keeps dropping but my opinion is this quarter will turn it around with UFC and other games along with the restructuring. Personally I'm thinking a buyout is going to come along. IMHO
Well looks like a few shorters bailed with a small profit so now let's move on. I'm loading up because as soon as the EU makes it official we are on the way back to $8. IMO
I sure am looking forward to another big rally here. ALIM has my mouth watering from the past two days action and now it's aern's turn! GLTA
More great news! I'm long on ALIM.
ALIMERA SCIENCES (ALIM) ILLUVIEN GETS POSITIVE EU NOD. COWEN KEEPS NEUTRAL
| S&P Marketscope
SNPMarketScopeViewsNews2012-02-28 15:01:10.000ALIMALIMERA SCIENCES, INC.STACY TROMBINOALIMERA SCIENCES (ALIM) ILLUVIEN GETS POSITIVE EU NOD. COWEN KEEPS NEUTRALAnalyst Simos Simeonidis says ALIM announces that European decentralized procedure was concluded with recommendation to approve Iluvien for treatment of chronic DME in 7 countries involved in the process. ALIM appears to be on step away from approval in these countries, which incl. 5 largest EU markets. Says final step should be completed by 3/28. Given run up in stock, uncertainty around financing, and reimbursement, launch and execution risks, and despite potential for upside to his ests, a takeout of co., sees risk/reward as balanced at current levels. S.Trombino|US;ALIM|2000013623|US|23783612
Preach it Surf! I'm locked and loaded for it. GLTA
It's probably going to teeter totter around the $3.90-$4.10 range until the last hour or so then I say a close around $4.50. JMHO
Alimera: Iluvien To Enter National Phase Of Approval Process In Europe
Font size: A | A | A
9:06 AM ET 2/28/12 | Dow Jones
DOW JONES NEWSWIRES
Alimera Sciences Inc. (ALIM) said its most advanced product, Iluvien, received a positive final assessment report from the Medicines and Healthcare products Regulatory Agency of the U.K., and will move to the next step in the approval process in Europe.
Several other countries also agreed that Iluvien, a treatment for diabetic macular edema, is approvable, the biopharmaceutical company said. The disease involves fluid retention in the back of the eye, impairing vision.
Shares of Alimera jumped 71% to $3.96 premarket while shares of its licensor pSivida Corp. (PSDV) rose 26% to $2.71.
Alimera said Iluvien will now enter the national phase of the decentralized procedure, in which the U.K. and the concerned member states of Austria, France, Germany, Italy, Portugal and Spain will each grant it a national license.
"Achieving a favorable conclusion for Iluvien in Europe is a significant milestone for Alimera and very encouraging for the many patients with this challenging chronic disease," said President and Chief Executive Dan Myers, president and chief executive. "We will continue to work closely with the U.K. and the concerned member states to ensure that Iluvien is made available to patients as soon as possible."
Alimera licensed Iluvien from pSivida, which will receive 20% of the net profit on sales if the drug is approved, plus a $25 million milestone payment.
In November, Alimera said the U.S. Food & Drug Administration has again requested additional safety and efficacy data to approve the application for Iluvien.
-By Nathalie Tadena, Dow Jones Newswires; 212-416-3287; nathalie.tadena@dowjones.com
> Dow Jones Newswires
IMO yes a very good buy still. It should double this week to $8
NICE but I'm saying $6 today! :)
I wish I hadn't lost faith in ALIM a few weeks ago when their earnings were suppose to be released and I got worried when they never did and I pulled the plug. But with Europe's approval now this baby will go back up to $8 and over where it was before the FDA asked for more testing. GO ALIM!!
I'm kicking myself for selling out a few weeks ago at $1.65 haha but I'm back in at $3.08 for the ride back up to $8 plus!
THIS IS HUGE!!! ALIM WILL SORE BACK TO $8+ WITH THIS NEWS!!
pSivida Corp. Announces Positive Outcome to European Decentralized Procedure for Approval of ILUVIEN(R) for the Treatment of Chronic Diabetic Macular Edema
6:36 AM ET 2/28/12 | BusinessWire
--ILUVIEN expected to be indicated for chronic DME considered insufficiently responsive to available therapies
pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced the positive outcome of the Decentralized Procedure (DCP) for the approval of ILUVIEN(R) in Europe. The announcement follows the issuance of the Final Assessment Report to pSivida's licensee Alimera Sciences, Inc. from the Reference Member State (RMS), the Medicines and Healthcare products Regulatory Agency of the United Kingdom (MHRA), and the agreement of all the Concerned Member States (CMS) that ILUVIEN is approvable.
The regulatory process will now enter the national phase of the DCP in which the RMS and each CMS grants its national license. The CMS include Austria, France, Germany, Italy, Portugal and Spain. ILUVIEN will be indicated for the treatment of vision impairment associated with chronic DME considered insufficiently responsive to available therapies.
The International Diabetes Federation estimates that, in these seven countries alone, 22.1 million people are currently living with diabetes. By comparison, the Centers for Disease Control and Prevention estimate that Americans with diabetes now number 25.8 million. Alimera estimates that within the seven CMS countries, 1.2 million people suffer from DME.
"I'm very pleased about this favorable outcome of the EU regulatory process for ILUVIEN," said Paul Ashton, president and chief executive officer of pSivida.
ILUVIEN is an injectable, sustained-release intravitreal insert that releases sub-microgram levels of fluocinolone acetonide (FAc) for up to 36 months for the treatment of chronic DME. pSivida is developing an insert of the same design for the treatment of uveitis affecting the posterior of the eye.
About pSivida Corp.
pSivida Corp., headquartered in Watertown, MA, develops tiny, sustained release, drug delivery products designed to deliver drugs at a controlled and steady rate for months or years. pSivida is currently focused on treatment of chronic diseases of the back of the eye utilizing its core technology systems, Durasert(TM) and BioSilicon(TM). ILUVIEN(R) for the treatment of Diabetic Macular Edema (DME), which is licensed to Alimera Sciences, Inc., is pSivida's most advanced product candidate, and based on a consensus arrived upon by the RMS and the CMS, the MHRA issued its Final Assessment Report that ILUVIEN for chronic DME is approvable. An investigator-sponsored Investigational New Drug application opened for an injectable insert to treat posterior uveitis of the same design as ILUVIEN for DME, and an investigator-sponsored trial is ongoing for an injectable, bioerodible insert to treat glaucoma and ocular hypertension. pSivida's two FDA-approved products, Retisert(R) and Vitrasert(R), are implants that provide long-term, sustained drug delivery to treat two other chronic diseases of the retina.
SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995: Various statements made in this release are forward-looking, and are inherently subject to risks, uncertainties and potentially inaccurate assumptions. All statements that address activities, events or developments that we intend, expect or believe may occur in the future are forward-looking statements. The following are some of the factors that could cause actual results to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements: Alimera's ability to successfully obtain regulatory approval of and commercialize ILUVIEN for DME in the EU; actions with respect to regulatory approval of ILUVIEN for DME in the U.S.; ability to obtain additional capital; ability to attain profitability; adverse side effects; exercise by Pfizer of the Latanoprost Product option; ability to complete clinical trials and obtain regulatory approval of product candidates; further impairment of intangible assets; fluctuations in operating results; decline in royalty revenues; ability to find partners to develop and market products; termination of license agreements; competition; market acceptance of products and product candidates; reduction in use of products as a result of future guidelines, recommendations or studies; ability to protect intellectual property and avoid infringement of others' intellectual property; retention of key personnel; product liability; consolidation in the pharmaceutical and biotechnology industries; compliance with environmental laws; manufacturing risks; risks and costs of international business operations; credit and financial market conditions; legislative or regulatory changes; volatility of stock price; possible dilution; possible influence by Pfizer; ability to pay any registration penalties; absence of dividends; and other factors described in our filings with the Securities and Exchange Commission. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. Our forward-looking statements speak only as of the dates on which they are made. We do not undertake any obligation to publicly update or revise our forward-looking statements even if experience or future changes makes it clear that any projected results expressed or implied in such statements will not be realized.
SOURCE: pSivida Corp.
I hope you are right. I have a lot invested in Thqi thanks to buying on the dips. This thing has more dips then a roller coaster.
Why are earnings now expected to be March 8th??
What's causing this jump?